Dr Reddy’s Laboratories will continue to strengthen its base business while building future growth drivers across peptides, biosimilars, consumer healthcare, and innovation-led therapies, according to its Chairman, K Satish Reddy and Co-Chairman and Managing Director G V Prasad.In their message to the shareholders in the annual report for the year 2025-26, the top leadership of the companies said: ``Our focus remains on consistent execution, disciplined capital allocation, and improving the quality and sustainability of our performance.’’Oncology pipeline and CDMO expansion in focusThe Hyderabad-based company’s oncology subsidiary, Aurigene Oncology, is advancing multiple programmes, with three assets currently in clinical development and several promising candidates in pre-clinical development. Efforts were on to build a differentiated global oncology business through a combination of internal innovation and partnerships, they said.In APIs and services, competitive pressures persist as customers increasingly move towards backward integration. ``In response, we are sharpening our focus on value through differentiated offerings and expanding our Contract Development and Manufacturing Organisation (CDMO) capabilities via Aurigene Pharmaceutical Services Ltd (APSL) to drive sustainable growth,’’ the leadership duo said.Biosimilars seen as future growth driverIn FY26, the API and North America generics businesses of Dr Reddy’s faced increased competitive intensity even as the biosimilars business was at an inflection point, they said, adding: “We are taking focused steps to scale it into a meaningful growth driver.’’Three strategic priorities for sustained growthThe company’s strategy would remain anchored in three priorities: strengthening core generics and API businesses through differentiated launches, targeted R&D, and supply chain reliability; expanding stable value pools through our consumer health portfolio; and building innovation-led growth platforms through selective partnerships and licensing, they added.Published on July 16, 2026